Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

Servi­er is walk­ing out on a part­ner­ship with Macro­Gen­ics $MGNX — for the sec­ond time.

Af­ter the mar­ket closed on Wednes­day Macro­Gen­ics put out word that Servi­er is sev­er­ing a deal — inked close to 7 years ago — to col­lab­o­rate on the de­vel­op­ment of flote­tuzum­ab and oth­er Dual-Affin­i­ty Re-Tar­get­ing (DART) drugs in its pipeline.

Macro­Gen­ics CEO Scott Koenig shrugged off the de­par­ture of Servi­er, which paid $20 mil­lion to kick off the al­liance and $20 mil­lion to op­tion flote­tuzum­ab — putting a heav­i­ly back-end­ed $1 bil­lion-plus in ad­di­tion­al biobuck mon­ey on the ta­ble for the an­ti-CD123/CD3 bis­pe­cif­ic and its com­pan­ion ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.